Terms: = Lung cancer AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1 AND Prognosis
102 results:
1. Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer.
Han R; Guo H; Shi J; Zhao S; Jia Y; Liu X; Liu Y; Cheng L; Zhao C; Li X; Zhou C
BMC Med; 2024 Apr; 22(1):174. PubMed ID: 38658988
[TBL] [Abstract] [Full Text] [Related]
2. Efficacy and safety of immunotherapy combined with single-agent chemotherapy as second- or later-line therapy for metastatic non-small cell lung cancer.
Chen D; Li L; Wang M; Hu X; Jiang J; Li W; Yang L; Fan M; Shi Y; Lv F; Liu Y
Front Immunol; 2023; 14():1086479. PubMed ID: 37795095
[TBL] [Abstract] [Full Text] [Related]
3. In vivo self-assembly and delivery of vegfr2 siRNA-encapsulated small extracellular vesicles for lung metastatic osteosarcoma therapy.
Yu L; Fan G; Wang Q; Zhu Y; Zhu H; Chang J; Wang Z; Zhan S; Hua X; She D; Huang J; Wang Y; Zhao J; Zhang CY; Chen X; Zhou G
Cell Death Dis; 2023 Sep; 14(9):626. PubMed ID: 37739958
[TBL] [Abstract] [Full Text] [Related]
4. Repeatedly next-generation sequencing during treatment follow-up of patients with small cell lung cancer.
JiaXin Y; XiaoFeng C; PengFei C; Songchen Z; Ziling L
Medicine (Baltimore); 2023 Jun; 102(26):e34143. PubMed ID: 37390276
[TBL] [Abstract] [Full Text] [Related]
5. Endocan Promotes Pro-Tumorigenic Signaling in lung cancer Cells: Modulation of Cell Proliferation, Migration and lncRNAs H19 and HULC Expression.
Aliquò F; Minuti A; Avenoso A; Mandraffino G; Campo GM; Campo S; D'Ascola A; Scuruchi M
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175885
[TBL] [Abstract] [Full Text] [Related]
6. Multi-Omics Immune Interaction Networks in lung cancer Tumorigenesis, Proliferation, and Survival.
Ye Q; Hickey J; Summers K; Falatovich B; Gencheva M; Eubank TD; Ivanov AV; Guo NL
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499305
[TBL] [Abstract] [Full Text] [Related]
7. A subset of vegfr-TKIs activates AMPK in LKB1-mutant lung cancer.
Yang L; Zhang Q; Xiong Y; Dang Z; Xiao H; Chen Q; Dai X; Zhang L; Zhu J; Wang D; Li M
Cancer Sci; 2023 Apr; 114(4):1651-1662. PubMed ID: 36459496
[TBL] [Abstract] [Full Text] [Related]
8. Identification of OTUD6B as a new biomarker for prognosis and immunotherapy by pan-cancer analysis.
Zhao G; Song D; Wu J; Yang S; Shi S; Cui X; Ren H; Zhang B
Front Immunol; 2022; 13():955091. PubMed ID: 36052059
[TBL] [Abstract] [Full Text] [Related]
9. Genome-wide DNA methylation signature predict clinical benefit of bevacizumab in non-small cell lung cancer.
Li B; Jiang C; Xu Y; Fan X; Yang L; Zou B; Fan B; Wang L
BMC Cancer; 2022 Jul; 22(1):828. PubMed ID: 35906610
[TBL] [Abstract] [Full Text] [Related]
10. Implication of
Li X; Cheng Y; Zhu B; Geng M; Yan P; Hu M
Technol Cancer Res Treat; 2022; 21():15330338221080993. PubMed ID: 35443836
[No Abstract] [Full Text] [Related]
11. The Effect of GLUT1 on the Survival Rate and Immune Cell Infiltration of lung Adenocarcinoma and Squamous Cell Carcinoma: A Meta and Bioinformatics Analysis.
Zhang G; Dong R; Kong D; Liu B; Zha Y; Luo M
Anticancer Agents Med Chem; 2022; 22(2):223-238. PubMed ID: 34238200
[TBL] [Abstract] [Full Text] [Related]
12. The Influence of kdr Genetic Variation on the Efficacy and Safety of Patients With Advanced NSCLC Receiving First-Line Bevacizumab Plus Chemotherapy Regimen.
Geng N; Su J; Liu Z; Ding C; Xie S; Hu W
Technol Cancer Res Treat; 2021; 20():15330338211019433. PubMed ID: 34060368
[TBL] [Abstract] [Full Text] [Related]
13. Effective treatment of anlotinib in giant delayed pulmonary metastasis of osteosarcoma: a case report and literature review.
Long ZY; Lu Y; Li M; Chen G; Shi L; Xiao X; Bai Y; Zhang HM; Wang Z
Ann Palliat Med; 2021 Jun; 10(6):7073-7082. PubMed ID: 33548989
[TBL] [Abstract] [Full Text] [Related]
14. Influence of vegfr2 gene polymorphism on the clinical outcomes of apatinib for patients with chemotherapy-refractory extensive-stage SCLC: a real-world retrospective study.
Geng N; Ding CM; Liu ZK; Song S; Hu WX
Int J Clin Oncol; 2021 Apr; 26(4):670-683. PubMed ID: 33392882
[TBL] [Abstract] [Full Text] [Related]
15. Concurrent Apatinib and Brain Radiotherapy in Patients With Brain Metastases From Driver Mutation-negative Non-small-cell lung cancer: Study Protocol for an Open-label Randomized Controlled Trial.
Ma J; Pi G; Bi J; Li Y; He H; Li Y; Hu D; Verma V; Han G
Clin Lung Cancer; 2021 Mar; 22(2):e211-e214. PubMed ID: 33187916
[TBL] [Abstract] [Full Text] [Related]
16. A novel variant of vegfr2 identified by a pan-cancer screening of recurrent somatic mutations in the catalytic domain of tyrosine kinase receptors enhances tumor growth and metastasis.
Grillo E; Corsini M; Ravelli C; di Somma M; Zammataro L; Monti E; Presta M; Mitola S
Cancer Lett; 2021 Jan; 496():84-92. PubMed ID: 33035615
[TBL] [Abstract] [Full Text] [Related]
17. Distinctive roles of syntaxin binding protein 4 and its action target, TP63, in lung squamous cell carcinoma: a theranostic study for the precision medicine.
Bilguun EO; Kaira K; Kawabata-Iwakawa R; Rokudai S; Shimizu K; Yokobori T; Oyama T; Shirabe K; Nishiyama M
BMC Cancer; 2020 Sep; 20(1):935. PubMed ID: 32993587
[TBL] [Abstract] [Full Text] [Related]
18. Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving vegfr-3 signaling.
Qin T; Liu Z; Wang J; Xia J; Liu S; Jia Y; Liu H; Li K
Cancer Biol Med; 2020 Aug; 17(3):753-767. PubMed ID: 32944404
[No Abstract] [Full Text] [Related]
19. Effect of malignant-associated pleural effusion on endothelial viability, motility and angiogenesis in lung cancer.
Changchien CY; Chen Y; Chang HH; Chang SY; Tsai WC; Tsai HC; Wang CY; Lee HS; Tsai CL
Cancer Sci; 2020 Oct; 111(10):3747-3758. PubMed ID: 32706142
[TBL] [Abstract] [Full Text] [Related]
20. [Clinical Analysis of Primary Pulmonary Lymphoepithelioma-like Carcinoma in 8 Patients].
Zhao H; Chen J
Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):168-175. PubMed ID: 32209185
[TBL] [Abstract] [Full Text] [Related]
[Next]
